Cullinan Therapeutics Reports $50.6 Million Net Loss in Q3 2025

Cullinan Therapeutics, Inc. reported a net loss of $50.6 million for the third quarter of 2025, compared to a loss of $40.6 million in the same period of 2024. For the nine months ending September 30, 2025, the company recorded a net loss of $169.2 million, up from $119.9 million in the prior year. Total operating expenses for the third quarter increased to $55.6 million from $48.9 million year-over-year, driven primarily by higher research and development costs, which rose to $42.0 million from $35.5 million. The increase in R&D expenses was attributed to clinical development costs and personnel costs associated with an expanded workforce.

In terms of financial position, Cullinan's total assets decreased to $484.1 million as of September 30, 2025, down from $621.8 million at the end of 2024. The decline was largely due to a reduction in short-term investments, which fell to $229.3 million from $316.0 million. Cash and cash equivalents, however, increased to $103.3 million from $83.0 million, reflecting a net increase in cash flow from investing activities, which provided $157.6 million during the nine months ended September 30, 2025, primarily from the maturities of marketable securities.

Strategically, Cullinan entered into a significant licensing agreement with Chongqing Genrix Biopharmaceutical Co., Ltd. in June 2025, granting the company a global license to develop and commercialize velinotamig, a bispecific T cell engager. The agreement included a $20 million upfront payment and potential milestone payments totaling up to $292 million. Additionally, the company has been actively pursuing its clinical pipeline, with ongoing trials for several product candidates, including zipalertinib and CLN-049, while also discontinuing development of CLN-619 and CLN-617 based on recent clinical data.

As of September 30, 2025, Cullinan had approximately 59.1 million shares of common stock outstanding, reflecting a slight increase from 58.5 million shares at the end of 2024. The company continues to face challenges typical of early-stage biopharmaceutical firms, including the need for substantial funding to support ongoing research and development efforts. Looking ahead, Cullinan expects to continue incurring operating losses and is focused on securing additional capital to fund its operations and advance its clinical programs. The company anticipates that its current cash and investments will be sufficient to meet its operational needs for at least the next twelve months.